Login to Your Account


Exithera Pharmaceuticals Inc. CEO Neil Hayward told BioWorld he's hoping to build a "continuum of care" around factor XIa inhibitor EP-7041, after phase I data showed the I.V. version of the antithrombotic safe and well-tolerated in healthy volunteers.

SHANGHAI – Genhui Chen, CEO and co-founder of Beijing Wenfeng Tianji Pharma Ltd., is at the end of a long road. He is an inventor-entrepreneur waiting patiently for the CFDA to give him good news.

Immunomolecular (IM) Therapeutics LLC, a company created to develop small-molecule therapies for the treatment of genetically defined autoimmune diseases, has revealed its lead candidate, an immunotherapy for type 1 diabetes, IMT-002

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: